Home
|
Help
|
Contact
Sign in
WPRIM Management System>
DCMS
>
Chinese Journal of Cancer
>
2016
>
35
>
12
Volume:
35
Issue:
12
1. Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
Page:641—644
2. Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma
Page:645—646
3. Combination therapy in cancer:effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics
Page:647—656
4. Development and validation of a nomogram for predicting the survival of patients with non-metastatic nasopharyngeal carcinoma after curative treatment
Page:658—665
5. MicroRNA-506 is up-regulated in the development of pancreatic ductal adenocarcinoma and is associated with attenuated disease progression
Page:666—672
6. Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy
Page:673—682
7. The clinical association of programmed cell death protein 4 (PDCD4) with solid tumors and its prognostic signiifcance:a meta-analysis
Page:683—698
8. Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma
Page:699—705
9. ABO blood group is a predictor of survival in patients with laryngeal cancer
Page:706—712
10. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma:a retrospective study
Page:713—724
11. Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy
Page:725—734
12. Study protocol of the Asian XELIRI ProjecT (AXEPT):a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the effcacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab
Page:735—742
13. Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma
Page:743—753